지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
이용수
등록된 정보가 없습니다.
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
Lean vs. obese phenotypes of nonalcoholic fatty liver disease: similar or different?
Clinical and Molecular Hepatology
2023 .04
Personalized medicine in nonalcoholic fatty liver disease
Clinical and Molecular Hepatology
2022 .10
The effect of moderate alcohol consumption on nonalcoholic fatty liver disease
Clinical and Molecular Hepatology
2023 .04
The Impact of Body Composition on the Prognosis of Nonalcoholic Fatty Liver Disease
Gut and Liver
2024 .07
A crystal ball to forecast treatment responsiveness in nonalcoholic fatty liver disease
Clinical and Molecular Hepatology
2022 .07
Screening and prediction of nonalcoholic fatty liver disease using a peripheral insulin resistance index: Potential benefits and limitations
Clinical and Molecular Hepatology
2022 .10
Nonalcoholic fatty liver disease-based risk prediction of adverse pregnancy outcomes: Ready for prime time?
Clinical and Molecular Hepatology
2022 .01
Non-obese or lean nonalcoholic fatty liver disease matters, but is it preventable or inevitable in light of its risk factors?
Clinical and Molecular Hepatology
2023 .04
The growing burden of non-alcoholic fatty liver disease on mortality
Clinical and Molecular Hepatology
2023 .04
Nonalcoholic Fatty Liver Disease Is a Stepping Stone in the Path toward Diabetes Mellitus
Gut and Liver
2019 .01
Implications of comorbidities in nonalcoholic fatty liver disease
Clinical and Molecular Hepatology
2023 .04
Hepatocellular carcinoma surveillance in non-alcoholic fatty liver disease – who and how?
Clinical and Molecular Hepatology
2023 .04
Probiotics for treatment of nonalcoholic fatty liver disease: It is worth a try
Clinical and Molecular Hepatology
2021 .01
Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments
Clinical and Molecular Hepatology
2023 .02
Response: Sarcopenia Is Significantly Associated with Presence and Severity of Nonalcoholic Fatty Liver Disease (J Obes Metab Syndr 2019;28:129-38)
Journal of Obesity & Metabolic Syndrome
2020 .01
Response: Sarcopenia Is Significantly Associated with Presence and Severity of Nonalcoholic Fatty Liver Disease (J Obes Metab Syndr 2019;28:129-38)
Journal of Obesity & Metabolic Syndrome
2020 .01
Letter: Sarcopenia Is Significantly Associated with Presence and Severity of Nonalcoholic Fatty Liver Disease (J Obes Metab Syndr 2019;28:129-38)
Journal of Obesity & Metabolic Syndrome
2020 .01
Letter: Sarcopenia Is Significantly Associated with Presence and Severity of Nonalcoholic Fatty Liver Disease (J Obes Metab Syndr 2019;28:129-38)
Journal of Obesity & Metabolic Syndrome
2020 .01
Changing the nomenclature from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease is more than a change in terminology
Clinical and Molecular Hepatology
2023 .04
Association of Myosteatosis with Nonalcoholic Fatty Liver Disease, Severity, and Liver Fibrosis Using Visual Muscular Quality Map in Computed Tomography
Diabetes and Metabolism Journal
2023 .01
0